Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study - Budde, LE; Assouline, S; Sehn, LH (J Clin Oncol, 2022)
et al.